PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 160 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2017. The put-call ratio across all filers is 1.25 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $189,910 | +26.1% | 35,832 | +3.0% | 0.02% | +30.8% |
| Q4 2023 | $150,571 | +75.4% | 34,774 | +6.5% | 0.01% | +30.0% |
| Q3 2023 | $85,841 | -25.5% | 32,639 | 0.0% | 0.01% | -16.7% |
| Q2 2023 | $115,216 | +16.9% | 32,639 | +2.4% | 0.01% | 0.0% |
| Q1 2023 | $98,522 | -18.3% | 31,884 | +11.9% | 0.01% | -33.3% |
| Q4 2022 | $120,538 | +79.9% | 28,496 | +1.0% | 0.02% | +100.0% |
| Q3 2022 | $67,000 | -16.2% | 28,205 | 0.0% | 0.01% | -10.0% |
| Q2 2022 | $80,000 | -2.4% | 28,205 | -1.3% | 0.01% | 0.0% |
| Q1 2022 | $82,000 | -79.9% | 28,571 | -10.7% | 0.01% | -81.8% |
| Q2 2019 | $407,000 | -62.1% | 32,000 | +76.5% | 0.06% | -51.3% |
| Q2 2018 | $1,073,000 | -21.7% | 18,132 | +15.6% | 0.11% | -38.6% |
| Q2 2017 | $1,371,000 | +185.6% | 15,685 | +21.6% | 0.18% | +109.1% |
| Q1 2017 | $480,000 | – | 12,900 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,300,000 | $13,338,000 | 2.17% |
| Camber Capital Management LP | 2,555,000 | $26,214,000 | 0.92% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,959,741 | $40,627,000 | 0.80% |
| Palo Alto Investors LP | 1,373,897 | $14,096,000 | 0.74% |
| Sofinnova Investments, Inc. | 629,650 | $6,460,000 | 0.38% |
| RICE HALL JAMES & ASSOCIATES, LLC | 604,937 | $6,207,000 | 0.22% |
| J. Goldman & Co LP | 238,617 | $2,448,000 | 0.12% |
| GLOBEFLEX CAPITAL L P | 55,027 | $565,000 | 0.12% |
| FRED ALGER MANAGEMENT, LLC | 3,416,003 | $35,048,000 | 0.09% |
| JUPITER ASSET MANAGEMENT LTD | 728,440 | $7,474,000 | 0.08% |